Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Satellos Bioscience (NASDAQ:MSLE) said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living with Duchenne muscular dystrophy, following a Type C interaction with the U.S. Food and Drug Administration. The company

Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk

Plus, news about MetaVia, Agios Pharmaceuticals and Inovio. Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed at helping muscle repair and growth in boys with Duchenne ...